• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.

作者信息

Hsieh Emily M, Myers Regina M, Yates Bonnie, Annesley Colleen, John Samuel, Taraseviciute Agne, Steinberg Seth M, Sheppard Jennifer, Chung Perry, Chen Lee, Lee Daniel W, DiNofia Amanda, Grupp Stephan A, Verneris Michael R, Laetsch Theodore W, Bhojwani Deepa, Brown Patrick A, Pulsipher Michael A, Rheingold Susan R, Gardner Rebecca A, Gore Lia, Shah Nirali N, Lamble Adam J

机构信息

Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.

出版信息

Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093.

DOI:10.1182/bloodadvances.2022008093
PMID:35834728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631644/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d74/9631644/c00b457ce4fd/advancesADV2022008093absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d74/9631644/c00b457ce4fd/advancesADV2022008093absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d74/9631644/c00b457ce4fd/advancesADV2022008093absf1.jpg

相似文献

1
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.CD19嵌合抗原受体T细胞疗法后后续恶性肿瘤发生率低。
Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093.
2
[Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer].嵌合抗原受体工程化T细胞治疗儿童癌症的临床研究进展
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Nov;19(11):1219-1224. doi: 10.7499/j.issn.1008-8830.2017.11.018.
3
Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages.门诊CD19导向的嵌合抗原受体T细胞疗法在各年龄段患者中均可行。
Br J Haematol. 2023 Nov;203(4):688-692. doi: 10.1111/bjh.19090. Epub 2023 Aug 29.
4
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.嵌合抗原受体 T 细胞疗法对 CD19 弱表达 B 淋巴细胞白血病有效，但会受到先前blinatumomab 治疗的影响。
Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.
5
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗Richter转化型弥漫性大B细胞淋巴瘤（DLBCL）后出现骨髓衰竭患者的寡克隆T细胞扩增
Blood. 2022 Nov 17;140(20):2175-2179. doi: 10.1182/blood.2022017015.
6
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.CD19嵌合抗原受体T细胞疗法治疗心脏淋巴瘤患者的可行性
Leuk Lymphoma. 2024 Mar;65(3):399-402. doi: 10.1080/10428194.2023.2288804. Epub 2023 Dec 9.
7
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.先前接受抗CD19嵌合抗原受体T细胞疗法治疗的患者随后发生的恶性肿瘤。
Blood Adv. 2024 May 28;8(10):2327-2331. doi: 10.1182/bloodadvances.2024012573.
8
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.用表达抗 CD19 嵌合抗原受体的 T 细胞治疗 B 细胞癌。
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
9
At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.实验台研究：嵌合抗原受体（CAR）T细胞疗法治疗B细胞恶性肿瘤
J Leukoc Biol. 2016 Dec;100(6):1255-1264. doi: 10.1189/jlb.5BT1215-556RR. Epub 2016 Oct 27.
10
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.细胞因子释放综合征和神经毒性的新见解：CD19 特异性嵌合抗原受体 T 细胞治疗后。
Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3.

引用本文的文献

1
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.慢性淋巴细胞白血病治疗现代 era 中的嵌合抗原受体 T 细胞
Cancers (Basel). 2025 Jan 15;17(2):268. doi: 10.3390/cancers17020268.
2
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.治疗相关髓系肿瘤：细胞毒性治疗、遗传因素和异常微环境之间的复杂相互作用。
Blood Cancer Discov. 2024 Nov 1;5(6):400-416. doi: 10.1158/2643-3230.BCD-24-0103.
3
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.

本文引用的文献

1
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.输注前因素对 CD19 CAR T 细胞回输后免疫表型复发的影响。
Blood Adv. 2023 Feb 28;7(4):575-585. doi: 10.1182/bloodadvances.2022007423.
2
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.儿童和青年急性淋巴细胞白血病患者接受 tisagenlecleucel 治疗后，微小残留病的下一代测序预测复发。
Blood Cancer Discov. 2022 Jan;3(1):66-81. doi: 10.1158/2643-3230.BCD-21-0095. Epub 2021 Dec 1.
3
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
接受嵌合抗原受体T细胞（CAR-T）治疗患者中的T细胞淋巴瘤：评估风险和因果关系
Blood. 2024 Dec 12;144(24):2473-2481. doi: 10.1182/blood.2024025828.
4
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?嵌合抗原受体 T 细胞疗法后继发性恶性肿瘤的现状：如何预防恶性肿瘤？
Int J Mol Sci. 2024 Sep 1;25(17):9518. doi: 10.3390/ijms25179518.
5
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase.嵌合抗原受体（CAR）T细胞疗法后第二原发性恶性肿瘤的特征：来自FAERS和VigiBase这两个全球药物警戒数据库的真实世界见解
EClinicalMedicine. 2024 Jun 20;73:102684. doi: 10.1016/j.eclinm.2024.102684. eCollection 2024 Jul.
6
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.CAR T 细胞治疗后第二肿瘤和 T 细胞淋巴瘤的风险。
N Engl J Med. 2024 Jun 13;390(22):2047-2060. doi: 10.1056/NEJMoa2401361.
7
Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T Cells.与 ATM 缺陷型 T 细胞的逆转录病毒 CAR 转导相关的遗传毒性。
Blood Cancer Discov. 2024 Jul 1;5(4):267-275. doi: 10.1158/2643-3230.BCD-23-0268.
8
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.儿童、青少年和年轻成年人接受嵌合抗原受体T细胞（CAR T细胞）治疗后发生T细胞恶性肿瘤的风险。
Blood Adv. 2024 Jul 9;8(13):3544-3548. doi: 10.1182/bloodadvances.2024013243.
9
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.LCAR-B38M嵌合抗原受体T细胞治疗复发或难治性多发性骨髓瘤患者的长期缓解与生存：LEGEND-2试验的5年随访
J Hematol Oncol. 2024 Apr 24;17(1):23. doi: 10.1186/s13045-024-01530-z.
10
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.双特异性抗体和 CAR-T 细胞：用于治疗大 B 细胞淋巴瘤的免疫疗法之争。
Blood Cancer J. 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w.
Blinatumomab 无应答和高疾病负担与 CD19-CAR 治疗 B-ALL 后的不良结局相关。
J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12.
4
Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors.一种癌症易感性筛查工具在预测儿童癌症幸存者后续恶性肿瘤方面的效用。
J Clin Oncol. 2021 Oct 10;39(29):3207-3216. doi: 10.1200/JCO.21.00018. Epub 2021 Aug 12.
5
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.tisagenlecleucel 在儿童和青少年 B 细胞急性淋巴细胞白血病中的安全性汇总分析。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2020-002287.
6
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.猪源 Bac 修饰的 CD19 嵌合抗原受体 T 细胞输注后产品相关淋巴瘤的研究。
Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858.
7
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.儿童 ALL 中全身放疗或化疗预处理：一项多国、随机、非劣效性 III 期研究。
J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17.
8
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.CAR T 细胞治疗后 B 细胞急性淋巴细胞白血病继发髓系恶性肿瘤的评估：诊断方法。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001563.
9
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞疗法的长期随访。
J Clin Oncol. 2020 Nov 10;38(32):3805-3815. doi: 10.1200/JCO.20.01467. Epub 2020 Oct 6.
10
Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study.儿童期急性淋巴细胞白血病幸存者的发病率和死亡率降低：来自儿童癌症幸存者研究的报告。
J Clin Oncol. 2020 Oct 10;38(29):3418-3429. doi: 10.1200/JCO.20.00493. Epub 2020 Jul 24.